Ornipressin acetate is a cyclic nonapeptide enriched in aromatic and basic residues that influence disulfide-linked folding. The sequence supports research in ring-constrained motifs, receptor-mimicking interactions, and solvent-dependent conformational changes. Researchers use it to investigate peptide stability and backbone dynamics. Its acetate form enhances solubility for analytical use.
CAT No: R2223
CAS No:914453-98-8
Synonyms/Alias:Ornipressin acetate;914453-98-8;acetic acid;(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;acetic acid; ornipressin;SCHEMBL4410141;GLXC-25929;AC-8926;H-Cys(1)-Tyr-Phe-Gln-Asn-Cys(1)-Pro-Orn-Gly-NH2 AcOH;
2. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
5. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.